⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

Official Title: A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

Study ID: NCT02019693

Conditions

Kidney Cancer

Interventions

INC280

Study Description

Brief Summary: Background: * Papillary Renal Cell Cancer (RCC) is the second most common histologic subtype of kidney cancer, accounting for approximately 10-15% of cases * Type 1 papillary RCC occurs in both sporadic and hereditary forms, which are histologically identical. Non familial type 1 papillary RCC can present as both solitary renal tumors and as bilateral, multifocal disease * There are no standard agents of proven efficacy for patients with advanced papillary RCC. * Patients with disease localized to the kidney are managed surgically while patients with advanced/unresectable disease are usually managed in the community with vascular endothelial growth factor (VEGF) pathway antagonists or mechanistic target of rapamycin (mTOR) inhibitors. * Activating mutations of mesenchymal epithelial transition (MET) were identified in the germline of affected hereditary papillary renal cancer (HPRC) patients, who have a predilection for the development of bilateral, multifocal type 1 papillary RCC. Somatic MET mutations have been found in a subset of patients with non-inherited, sporadic papillary renal carcinoma * The investigational agent Capmatinib (INC280) is a selective MET inhibitor lacking activity against the VEGF pathway * This is a proof-of-concept study using INC280 in patients with papillary RCC to test the idea that effectively blocking the hepatocyte growth factor (HGF)/MET pathway will lead to clinical activity in patients with papillary renal cell cancer Objectives: Primary Objective: -To determine the overall response rate (Response Evaluation Criteria in Solid Tumors (RECIST) 1.1) in patients with papillary renal cell carcinoma treated with single agent INC280 Eligibility: * Diagnosis of hereditary papillary renal carcinoma (HPRC) or sporadic papillary renal cell carcinoma (RCC) * Patients with bilateral multifocal disease can have tumors localized to the kidney or have metastatic disease * Patients with sporadic papillary RCC (but without multifocal disease) should have advanced disease that is considered unresectable * Eastern Cooperative Oncology Group (ECOG) 0-2 * Measurable disease * Adequate organ function * No active brain metastases * Prior therapy * No more than 3 prior lines of systemic therapy * Prior therapy with a MET inhibitor is allowed as long as the patient has not had progressive disease while receiving the agent Design: * This is a phase 2 single center non-randomized trial. * The study will be conducted using a Simon 2 stage minimax design. Initially 13 evaluable subjects will be recruited. If there are no responses to therapy, the study will be terminated. If there is at least 1 response an additional 7 evaluable subjects will be accrued. * The two-stage minimax design is based on assuming an ineffective response rate of 5% and a targeted effective response rate of 25%. We also assume that the probability of accepting an ineffective treatment and the probability of rejecting an effective treatment are each 10%. * Subjects will be dosed orally at a starting dose of 600 mg twice daily. * The overall response rate (complete response + partial response) will be determined.

Detailed Description: Background: * Papillary Renal Cell Cancer (RCC) is the second most common histologic subtype of kidney cancer, accounting for approximately 10-15% of cases * Type 1 papillary RCC occurs in both sporadic and hereditary forms, which are histologically identical. Non familial type 1 papillary RCC can present as both solitary renal tumors and as bilateral, multifocal disease * There are no standard agents of proven efficacy for patients with advanced papillary RCC. * Patients with disease localized to the kidney are managed surgically while patients with advanced/unresectable disease are usually managed in the community with vascular endothelial growth factor (VEGF) pathway antagonists or mechanistic target of rapamycin (mTOR) inhibitors. * Activating mutations of mesenchymal epithelial transition (MET) were identified in the germline of affected HPRC patients, who have a predilection for the development of bilateral, multifocal type 1 papillary RCC. Somatic MET mutations have been found in a subset of patients with non-inherited, sporadic papillary renal carcinoma * The investigational agent Capmatinib (INC280) is a selective MET inhibitor lacking activity against the VEGF pathway * This is a proof-of-concept study using INC280 in patients with papillary RCC to test the idea that effectively blocking the hepatocyte growth factor (HGF)//MET pathway will lead to clinical activity in patients with papillary renal cell cancer Objectives: Primary Objective: -To determine the overall response rate (Response Evaluation Criteria in Solid Tumors (RECIST) 1.1) in patients with papillary renal cell carcinoma treated with single agent INC280 Eligibility: * Diagnosis of hereditary papillary renal carcinoma (HPRC) or sporadic papillary renal cell carcinoma (RCC) * Patients with bilateral multifocal disease can have tumors localized to the kidney or have metastatic disease * Patients with sporadic papillary RCC (but without multifocal disease) should have advanced disease that is considered unresectable * Eastern Cooperative Oncology Group (ECOG) 0-2 * Measurable disease * Adequate organ function * No active brain metastases * Prior therapy * No more than 3 prior lines of systemic therapy * Prior therapy with a MET inhibitor is allowed as long as the patient has not had progressive disease while receiving the agent Design: * This is a phase 2 single center non-randomized trial. * The study will be conducted using a Simon 2 stage minimax design. Initially 13 evaluable subjects will be recruited. If there are no responses to therapy, the study will be terminated. If there is at least 1 response an additional 7 evaluable subjects will be accrued. * The two-stage minimax design is based on assuming an ineffective response rate of 5% and a targeted effective response rate of 25%. We also assume that the probability of accepting an ineffective treatment and the probability of rejecting an effective treatment are each 10%. * Subjects will be dosed orally at a starting dose of 400 mg twice daily. * The overall response rate (complete response + partial response) will be determined.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Contact Details

Name: Ramaprasad Srinivasan, M.D.

Affiliation: National Cancer Institute (NCI)

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: